Dr Anna Minchom is a BRC Clinical Scientist and Consultant Medical Oncologist in the Drug Development Unit and the Lung Unit at the Royal Marsden Hospital and a team leader at the Institute of Cancer Research.
Dr Minchom’s research interests involve utilising biomarker-driven and translational approaches to develop novel drugs and drug combinations for both lung cancer and mesothelioma. Several of Dr Minchom’s publications are focused on targeted therapies for NSCLC, such as EGFR TKIs, and the resistance mechanisms that develop when patients are treated with such therapies. Dr Minchom also partakes in research to identify novel genetic markers in lung cancer to broaden the scope of personalised treatments.
Dr Minchom serves as a Principal Investigator on several national and international early phase drug trials, including first-in-human clinical studies. Many of these trials focus on novel treatment modalities such as immunotherapies, radioimmunoconjugates, signalling molecule inhibitors, and antibody-drug conjugates. Dr Minchom has also presented at numerous congresses including the American Society of Clinical Oncology (ASCO 2021) discussing real-world outcomes in patients with EGFR exon 20 insertion mutations. Whilst training in Medical Oncology, Dr Minchom was awarded an MD(res) in recognition of her laboratory research focused on investigating the resistance mechanisms that underly targeted drug treatment in NSCLC.
EM-89207 - Date of preparation: February 2022